U.S. Markets closed
  • S&P 500

    4,429.10
    +26.44 (+0.60%)
     
  • Dow 30

    35,064.25
    +271.58 (+0.78%)
     
  • Nasdaq

    14,895.12
    +114.58 (+0.78%)
     
  • Russell 2000

    2,200.58
    -23.00 (-1.03%)
     
  • Crude Oil

    68.47
    -2.09 (-2.96%)
     
  • Gold

    1,813.60
    -0.50 (-0.03%)
     
  • Silver

    25.47
    -0.11 (-0.44%)
     
  • EUR/USD

    1.1844
    -0.0024 (-0.2013%)
     
  • 10-Yr Bond

    1.2170
    +0.0330 (+2.79%)
     
  • Vix

    17.94
    -0.10 (-0.55%)
     
  • GBP/USD

    1.3900
    -0.0015 (-0.1070%)
     
  • USD/JPY

    109.4750
    +0.4250 (+0.3897%)
     
  • BTC-USD

    40,876.99
    +924.69 (+2.31%)
     
  • CMC Crypto 200

    1,005.54
    +29.64 (+3.04%)
     
  • FTSE 100

    7,123.86
    +18.14 (+0.26%)
     
  • Nikkei 225

    27,584.08
    -57.75 (-0.21%)
     

Forma Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on May 14, 2021

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that it will release first quarter 2021 financial results on Friday, May 14, 2021. Forma management will host an investment community conference call at 8 a.m. Eastern Time, on May 14, 2021, to discuss these financial results and provide a business update.

Investors may participate by dialing (833) 301-1146 in the U.S. or Canada, or (914) 987-7386 internationally, and by referring to Conference ID 8597396. A live webcast of the conference call will be available in the "News & Investors" section of Forma’s website at www.formatherapeutics.com.

About Forma Therapeutics

Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Our R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create drug candidates with differentiated mechanisms of action focused on indications with high unmet need. Our work has generated a broad proprietary portfolio of programs with the potential to provide profound patient benefit. For more information, please visit www.FormaTherapeutics.com or follow us on Twitter @FORMAInc and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210506005409/en/

Contacts

Investor Contact:
Mario Corso, +1 781-366-5726
Forma Therapeutics, Inc.
mcorso@formatherapeutics.com